Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева yubykov@gmail.com
Список исп. литературыСкрыть список 1. Вельтищев Д.Ю. Некоторые психотропные и соматотропные эффекты сертралина (Золофта) при лечении депрессий у больных общей медицинской практики. Психические расстройства в общей медицине. 2013; 3: 53–7. / Vel'tishchev D.Iu. Nekotorye psikhotropnye i somatotropnye effekty sertralina (Zolofta) pri lechenii depressii u bol'nykh obshchei meditsinskoi praktiki. Mental Disorders in General Medicine. 2013; 3: 53–7. [in Russian] 2. Волошин В.М. и др. Применение сертралина в детско-подростковой психиатрической практике. Конгресс по детской психиатрии. 2001; с. 240–1. / Voloshin V.M. i dr. Primenenie sertralina v detsko-podrostkovoi psikhiatricheskoi praktike. Kongress po detskoi psikhiatrii. 2001; s. 240–1. [in Russian] 3. Данилов А.Б. Золофт. Возможности клинического применения. Рус. мед. журн. 2007; 24: 1828–33. / Danilov A.B. Zoloft. Vozmozhnosti klinicheskogo primeneniia. Rus. med. zhurn. 2007; 24: 1828–33. [in Russian] 4. Корнетов Н.А. Сертралин (золофт): новый в России селективный антидепрессант и его значение в терапии типичных депрессивных расстройств. Сиб. вестн. психиатрии и наркологии. 1998; 3: 65–79. / Kornetov N.A. Sertralin (zoloft): novyi v Rossii selektivnyi antidepressant i ego znachenie v terapii tipichnykh depressivnykh rasstroistv. Sib. vestn. psikhiatrii i narkologii. 1998; 3: 65–79. [in Russian] 5. Кравченко Н.Е. Клиническая эффективность стимулотона при лечении непсихотических депрессивных расстройств у подростков. Психиатрия. 2005; 1 (13): 50–4. / Kravchenko N.E. Klinicheskaia effektivnost' stimulotona pri lechenii nepsikhoticheskikh depressivnykh rasstroistv u podrostkov. Psikhiatriia. 2005; 1 (13): 50–4. [in Russian] 6. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПБ.: Береста, 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPB.: Beresta, 2012. [in Russian] 7. Малинина Е.В., Забозлаева И.В. Применение торина (сертралина) в лечении депрессивных и обсессивно-компульсивных расстройств в детском возрасте. Журн. неврологии и психиатрии им. С.С.Корсакова. 2010; 110 (8): 22–4. / Malinina E.V., Zabozlaeva I.V. Primenenie torina (sertralina) v lechenii depressivnykh i obsessivno-kompul'sivnykh rasstroistv v detskom vozraste. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2010; 110 (8): 22–4. [in Russian] 8. Можгинский Ю. Золофт в терапии патологической агрессивности в детском возрасте. Врач. 2005; 2: 58–61. / Mozhginskii Iu. Zoloft v terapii patologicheskoi agressivnosti v detskom vozraste. Vrach. 2005; 2: 58–61. [in Russian] 9. Морозов П.В. Золофт (сертралин) в психиатрии и общей медицинской практике: данные последних лет. Психиатрия и психофармакотерапия. 2003; 5 (3): 1304. / Morozov P.V. Zoloft (sertralin) v psikhiatrii i obshchei meditsinskoi praktike: dannye poslednikh let. Psychiatry and Psychopharmacotherapy. 2003; 5 (3): 1304. [in Russian] 10. Поздеева Е.А., Морозов П.В. Золофт (сертралин) в клинической практике (обзор). Психиатрия и психофармакотерапия. 2008; 10 (5): 34–9. / Pozdeeva E.A., Morozov P.V. Zoloft (sertralin) v klinicheskoi praktike (obzor). Psychiatry and Psychopharmacotherapy. 2008; 10 (5): 34–9. [in Russian] 11. Чахава К.О. Депрефолт (Сертралин) – обзор терапевтического профиля. Психиатрия и психофармакотерапия. 2007; 9 (3): 37–43. / Chakhava K.O. Deprefolt (Sertralin) – obzor terapevticheskogo profilia. Psychiatry and Psychopharmacotherapy. 2007; 9 (3): 37–43. [in Russian] 12. Ambrosini PJ, Wagner KD, Biederman J et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 1999; 38 (5): 566–72. 13. Axelson DA, Perel JM, Birmaher B et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002; 41 (9): 1037–44. 14. Belli H, Akbudak M, Ural C, Aslaner D. A Case of Depersonalization with Treatment-resistant Depression Successfully Treated with Sertraline-lamotrigine Combination. West Indian Med J 2014; 63 (1): 115. 15. Çakin Memik N, Karakaya I, Yildiz Ö et al. The Effect of Sertraline on the Quality of Life for Children and Adolescents with Anxiety Disorder. Noro Psikiyatr Ars 2014; 51 (1): 30–9. 16. Compton SN, Grant PJ, Chrisman AK et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (5): 564–71. 17. Cook EH, Wagner KD, March JS et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40 (10): 1175–181. 18. Demolis JL, Angebaud P, Grange JD et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996; 42: 394–7. 19. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247–66. 20. Donnelly CL, Winoker A, Wohlberg CJ. Effficacy and safety of sertraline in the treatment of pediatric major depressive disorder (poster). Presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting; December 9–13, 2001; Waikoloa, Hawaii. 21. Donnelly CL, Wagner KD, Rynn M et al. Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry 2006; 45 (10): 1162–70. 22. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiat 1988; 49 (Suppl.): 46–51. 23. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharm 1991; 6 (Suppl.): 2: 47–56. 24. Dougherty DD, Loh R, Jenike MA, Keuthen NJ. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry 2006; 67 (7): 1086–92. 25. Duggal HS, Basu S, Dutta S, Sinha VK. Sertraline and buspirone in adolescent delusional body dysmorphic disorder. Indian J Psychiatry 2001; 43 (4): 370–1. 26. El-Khatib HE, Dickey TO 3rd. Sertraline for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry 1995; 34 (11): 1404–5. 27. FDA Generic Equivalency Requirements, 2018. Available online at FDA. 28. FDA Orange Book, 2018. Available online at FDA. 29. Feeney DJ, Klykylo WM. Treatment for kleptomania. J Am Acad Child Adolesc Psychiatry 1997; 36 (6): 723–4. 30. Foguet Q, Alvárez MJ, Castells E, Arrufat F. Methylphenidate in depersonalization disorder: a case report. Actas Esp Psiquiatr 2011; 39 (1): 75–8. 31. Frankenburg FR, Kando JC. Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome. J Clin Psychopharmacol 1994; 14 (5): 359–60. 32. Goodnik PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. J Basic Pharmacol 1998; 12: 5–20. 33. Günther T, Holtkamp K, Jolles J et al. The influence of sertraline on attention and verbal memory in children and adolescents with anxiety disorders. J Child Adolesc Psychopharmacol 2005; 15 (4): 608–18. 34. Heym J, Koe BK. Pharmacology of sertraline: A review. J Clin Psychiatry 1988; 49 (Suppl.): 40–5. 35. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28. 36. Johnston HF. The efficacy of sertraline and behavior therapy in adolescents with treatment resistant OCD (abstract). Presented at the 14th Annual Meeting of the American Psychiatric Association; May 23–26, 1993: San Francisco, CA. 37. Khouzam HR, Emes R, Gill T, Raroque R. The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Compr Ther 2003; 29 (1): 47–53. 38. Ko SM. Under-diagnosed psychiatric syndrome. II: Pathologic skin picking. Ann Acad Med Singapore 1999; 28 (4): 557–9. 39. Koe BK, Koch SW, Lebel LA et al. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of beta-adrenoceptor system of rat brain. Eur J Pharmacol 1987; 141: 187–94. 40. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 226: 686–700. 41. Kotcher L, Wieland N, Coffey B. Trichotillomania and co-morbid psychiatric disorders in a 10-year-old boy. J Child Adolesc Psychopharmacol 2007; 17 (1): 137–41. 42. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 2001; 7 (1): 1–24. 43. Mancini-Marïe A, Fahim C, Potvin S et al. Quetiapine: focus on emotional numbing in depersonalization disorder: an fMRI case report. Eur Psychiatry 2006; 21 (8): 574–7. 44. March JS, Biederman J, Wolkow R et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280: 1752–6. 45. McConville BJ, Minnery KL, Sorter MT et al. An open study of the effects of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 1996; 6 (1): 41–51. 46. McRae AL, Brady KT. Review of sertraline and its clinical applications in psychiatric disorders. Exp Opin Pharmacother 2001; 2 (5): 883–92. 47. Meroni MC, Lo Giudice A, Kotzalidis GD, Biondi M. Improvement of pathologic gambling symptoms after administration of sertraline: a case report. J Clin Psychopharmacol 2004; 24 (3): 350–1. 48. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44 (4): 604–24. 49. Nixon MK, Milin R, Simeon JG et al. Sertraline effects in adolescent major depression and dysthymia: a six-month open trial. J Child Adolesc Psychopharmacol 2001; 11 (2): 131–42. 50. Nutt D, Lawson C. Panic attacks: A neurochemical overview of models and mechanisms. Br J Psychiatry 1992; 160: 165–78. 51. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33 (2): 262–70. 52. Park P, Caballero J, Omidian H. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics. Ann Pharmacother 2014; 48 (1): 86–92. 53. Pediatric OCD Treatment Study (POTS) Team. Cognitive behavior therapy, sertraline, and their combination for children and adolescents with obsessive–compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292: 1969–76. 54. Preve M, Mula M, Cassano GB, Pini S. Venlafaxine in somatopsychic and autopsychic depersonalization. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (8): 1808–9. 55. Pujol JF, Keane P, McCrae A et al. Biochemical evidence for serotonergic control of the locus coeruleus. In: Garatini S, Pujol JF, Samanin R, eds. Interactions between putative neurotransmitters in the brain. New York: Raven Press; 1978: p. 401–10. 56. Robb AS, Cueva JE, Sporn J et al. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2010; 20 (6): 463–71. 57. Rodríguez-Ramos P, Mardomingo Sanz MJ. Response to sertraline in adolescents with obsessive-compulsive disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998; 26 (1): 17–21. 58. Rynn M, Wagner KD, Donnelly C et al. Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006; 16 (1–2): 103–16. 59. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158: 2008–14. 60. Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol 2001; 11 (2): 143–50. 61. Scarella TM, Franzen JR. Case report: Improvement in dissociative symptoms with mixed amphetamine salts. J Trauma Dissociation 2017; 18 (5): 649–62. 62. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. Cambridge University Press. 1st Ed. 2012. 186 p. ISBN 978-0521874984. 63. Sloan DM, Mizes JS, Helbok C, Muck R. Efficacy of sertraline for bulimia nervosa. Int J Eat Disord 2004; 36 (1): 48–54. 64. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4rd Ed. 2013. ISBN 978-1107686465. 65. Stoddard FJ Jr, Luthra R, Sorrentino EA et al. A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol 2011; 21 (5): 469–77. 66. Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav 2007; 10 (3): 417–25. 67. Tierney E, Joshi PT, Llinas JF et al. J Child Adolesc Psychopharmacol 1995; 5: 13–27. 68. Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290 (8): 1033–41. 69. Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003; 13 (Suppl. 1): S53–60. 70. Walkup JT, Albano AM, Piacentini J et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359 (26): 2753–66. 71. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991; 6 (Suppl. 2): 11–21.